{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:48:44Z","timestamp":1784198924245,"version":"3.55.0"},"reference-count":61,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T00:00:00Z","timestamp":1550275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Healthcare"],"abstract":"<jats:p>Rational medicine use in neonates implies the prescription and administration of age-appropriate drug formulations, selecting the most efficacious and safe dose, all based on accurate information on the drug and its indications in neonates. This review illustrates that important uncertainties still exist concerning the different aspects (when, what, how) of rational antibiotic use in neonates. Decisions when to prescribe antibiotics are still not based on robust decision tools. Choices (what) on empiric antibiotic regimens should depend on the anticipated pathogens, and the available information on the efficacy and safety of these drugs. Major progress has been made on how (beta-lactam antibiotics, aminoglycosides, vancomycin, route and duration) to dose. Progress to improve rational antibiotic use necessitates further understanding of neonatal pharmacology (short- and long-term safety, pharmacokinetics, duration and route) and the use of tailored tools and smarter practices (biomarkers, screening for colonization, and advanced therapeutic drug monitoring techniques). Implementation strategies should not only facilitate access to knowledge and guidelines, but should also consider the most effective strategies (\u2018skills\u2019) and psychosocial aspects involved in the prescription process: we should be aware that both the decision not to prescribe as well as the decision to prescribe antibiotics is associated with risks and benefits.<\/jats:p>","DOI":"10.3390\/healthcare7010028","type":"journal-article","created":{"date-parts":[[2019,2,17]],"date-time":"2019-02-17T22:11:50Z","timestamp":1550441510000},"page":"28","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Rational Use of Antibiotics in Neonates: Still in Search of Tailored Tools"],"prefix":"10.3390","volume":"7","author":[{"given":"John","family":"van den Anker","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Pediatrics, Children\u2019s National Health System, 111 Michigan Avenue NW, Washington, DC 20010, USA"},{"name":"Division of Paediatric Pharmacology and Pharmacometrics, University of Basel Children\u2019s Hospital, Spitalstrasse 33,  4056 Basel, Switzerland"},{"name":"Intensive Care, Erasmus MC-Sophia Children\u2019s Hospital, Dr Molewaterplein 40,  3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-5105","authenticated-orcid":false,"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Neonatology, Erasmus MC-Sophia Children\u2019s Hospital, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"},{"name":"Department of Development and Regeneration, KU Leuven, Herestraat 49,  3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,2,16]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2019, January 12). Essential Medicines and Health Products. The Pursuit of Responsible Use of Medicines. Available online: htpps:\/\/www.who.int\/medicines\/areas\/rational_use\/en."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fphar.2017.00027","article-title":"Drug utilization on neonatal wards: A systematic review of observational studies","volume":"8","author":"Rosli","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10096-010-0990-3","article-title":"Quantifying antibiotic use in paediatrics: A proposal for neonatal DDDs","volume":"29","author":"Liem","year":"2010","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11096-018-0589-9","article-title":"Comparison of antibiotic dosing recommendations for neonatal sepsis from established reference sources","volume":"40","author":"Liem","year":"2018","journal-title":"Int. J. Clin. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00228-017-2200-z","article-title":"Off-label use of antimicrobials in neonates in a tertiary children\u2019s hospital","volume":"73","author":"Laine","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00228-012-1354-y","article-title":"Methods in pharmacoepidemiology: A review of statistical analyses and data reporting in pediatric drug utilization studies","volume":"69","author":"Sequi","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1055\/s-0033-1361933","article-title":"Best Pharmaceuticals for Children Act-Pediatric Trials Network. Medication use in the neonatal intensive care unit","volume":"31","author":"Hsieh","year":"2014","journal-title":"Am. J. Perinatol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nellis, G., Lutsar, I., Varendi, H., Toompere, K., Turner, M.A., Duncan, J., and Metsvaht, T. (2014). Comparison of two alternative study designs in assessment of medicines utilisation in neonates. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-89"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijpharm.2013.08.078","article-title":"European study of neonatal exposure to excipients: An update","volume":"457","author":"Turner","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The antibiotic resistance and prescribing in European Children project: A neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide","volume":"32","author":"Versporten","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Allegaert, K. (2018). Rational use of medicines in neonates: Current observations, areas for research and perspectives. Healthcare, 6.","DOI":"10.3390\/healthcare6030115"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/pr.2016.221","article-title":"Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates","volume":"81","author":"Ward","year":"2017","journal-title":"Pediatr. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"F141","DOI":"10.1136\/adc.2007.120709","article-title":"Improving antibiotic prescribing in neonatal units: Time to act","volume":"97","author":"Russell","year":"2012","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fped.2018.00285","article-title":"Culture-negative early-onset neonatal sepsis\u2014At the crossroad between efficient sepsis care and antimicrobial stewardship","volume":"6","author":"Klingenberg","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jamapediatrics.2016.4678","article-title":"A quantitative, risk-based approach to the management of neonatal early-onset sepsis","volume":"171","author":"Kuzniewicz","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1203\/01.PDR.0000064904.05313.D2","article-title":"Abnormal heart rate characteristics preceding neonatal sepsis and sepsis-like illness","volume":"53","author":"Griffin","year":"2003","journal-title":"Pediatr. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"F329","DOI":"10.1136\/archdischild-2015-309210","article-title":"Heart rate characteristic index monitoring for bloodstream infection in a NICU: A 3-year experience","volume":"101","author":"Coggins","year":"2016","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Litz, J.E., Goedicke-Fritz, S., H\u00e4rtel, C., Zemlin, M., and Simon, A. (2019). Management of early- and late-onset sepsis: Results from a survey in 80 German NICUs. Infection.","DOI":"10.1007\/s15010-018-1263-9"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0022-3476(96)70254-8","article-title":"Volume of blood required to detect common neonatal pathogens","volume":"129","author":"Schelonka","year":"1996","journal-title":"J. Pediatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"F248","DOI":"10.1136\/archdischild-2014-306349","article-title":"NICE neonatal early onset sepsis guidance: Greater consistency, but more investigations, and greater length of stay","volume":"100","author":"Mukherjee","year":"2015","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(17)31444-7","article-title":"Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: A multicenter, randomised controlled trial (NeoPins)","volume":"390","author":"Stocker","year":"2017","journal-title":"Lancet"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fped.2018.00325","article-title":"Key components for antibiotic dose optimization of sepsis in neonates and infants","volume":"6","author":"Bielicki","year":"2018","journal-title":"Front. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/INF.0000000000000031","article-title":"Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: A large multicenter study form the German Neonatal Network","volume":"33","author":"Faust","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/jp.2013.155","article-title":"Coagulase-negative staphylococcus sepsis in preterm infants and long-term neurodevelopmental outcome","volume":"34","author":"Alshaikh","year":"2014","journal-title":"J. Perinatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/archdischild-2013-305309","article-title":"Therapeutic drug monitoring in neonates","volume":"101","author":"Pauwels","year":"2016","journal-title":"Arch. Dis. Child."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/jac\/dkx088","article-title":"Antibiotic exposure in neonates and early adverse outcomes: A systematic review and meta-analysis","volume":"72","author":"Esaiassen","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0140-6736(00)90015-1","article-title":"An antibiotic policy to prevent emergence of resistant bacilli","volume":"355","author":"Verhoeven","year":"2000","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Allegaert, K., and van den Anker, J. (2018). Neonates are not just little children and need more finesse in dosing of antibiotics. Acta. Clin. Belg.","DOI":"10.1080\/17843286.2018.1473094"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.2174\/1381612823666170925162143","article-title":"Optimising \u03b2\u2013lactam dosing in neonates: A review of pharmacokinetics, drug exposure and pathogens","volume":"23","author":"Fuchs","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1179\/acb.2008.003","article-title":"Developmental pharmacology: Neonates are not just small adults\u2026","volume":"63","author":"Allegaert","year":"2008","journal-title":"Acta Clin. Belg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/archdischild-2013-304887","article-title":"Intravenous drug delivery in neonates: Lessons learnt","volume":"99","author":"Sherwin","year":"2014","journal-title":"Arch. Dis. Child."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/archdischild-2014-306873","article-title":"Therapeutic guidelines for prescribing antibiotics in neonates should be evidence-based: A French national survey","volume":"100","author":"Leroux","year":"2015","journal-title":"Arch. Dis. Child."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Metsvaht, T., Nellis, G., Varendi, H., Nunn, A.J., Graham, S., Rieutord, A., Storme, T., McElnay, J., Mulla, H., Turner, M.A., and Lutsar, I. (2015). High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: Implications for research and dissemination. BMC Pediatr., 15.","DOI":"10.1186\/s12887-015-0359-y"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/archdischild-2016-311674","article-title":"Developing a paediatric drug formulary for the Netherlands","volume":"102","author":"Liem","year":"2017","journal-title":"Arch. Dis. Child."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e01663-17","DOI":"10.1128\/AAC.01663-17","article-title":"Seventy-five years of research on protein binding","volume":"62","author":"Dalhoff","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/jcph.705","article-title":"Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates","volume":"56","author":"Wilbaux","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/jac\/dkt527","article-title":"Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates","volume":"69","author":"Smits","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","first-page":"S10","article-title":"Developmental changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"Reed","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/cpt.166","article-title":"Neonatal drug therapy: The first frontier of therapeutics for children","volume":"98","author":"Allegaert","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e02238-17","DOI":"10.1128\/AAC.02238-17","article-title":"Pharmacokinetics of penicillin G in preterm and term neonates","volume":"62","author":"Padari","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6626","DOI":"10.1128\/AAC.01045-16","article-title":"A population and developmental pharmacokinetic analysis to evaluate and optimize cefotaxime dosing regimen in neonates and young infants","volume":"60","author":"Leroux","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1128\/AAC.00351-09","article-title":"Meropenem pharmacokinetics in the newborn","volume":"53","author":"Pokorna","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/INF.0000000000001445","article-title":"Conventional versus prolonged infusion of meropenem in neonates with Gram-negative late-onset sepsis: A randomized controlled trial","volume":"36","author":"Shabaan","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/17425255.2017.1234606","article-title":"The amikacin research program: A stepwise approach to validate dosing regimens in neonates","volume":"13","author":"Smits","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e01282-17","DOI":"10.1128\/AAC.01282-17","article-title":"Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia","volume":"61","author":"Cristea","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000079618","article-title":"Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life","volume":"86","author":"Allegaert","year":"2004","journal-title":"Biol. Neonate"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e02004-17","DOI":"10.1128\/AAC.02004-17","article-title":"Quantitative analysis of gentamicin exposure in neonates and infants calls into question its current dosing recommendations","volume":"62","author":"Pfister","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/jac\/dkv052","article-title":"Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates","volume":"70","author":"Valitalo","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s11095-013-1197-y","article-title":"A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates","volume":"31","author":"Allegaert","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Drennan, P.G., Begg, E.J., Gardiner, S.J., Kirkpatrick, C.M.J., and Chambers, S.T. (2018). The dosing and monitoring of vancomycin\u2014What it the best way forward?. Int. J. Antimicrob. Agents.","DOI":"10.1016\/j.ijantimicag.2018.12.014"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/FTD.0000000000000456","article-title":"DosOpt: a tool for personalized Bayesian dose adjustment of vancomycin in neonates","volume":"39","author":"Tasa","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/j.1365-2125.2012.04406.x","article-title":"External evaluation of population pharmacokinetic models of vancomycin in neonates: The transferability of published models to different clinical settings","volume":"75","author":"Zhao","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s10096-012-1703-x","article-title":"Cefazolin plasma protein binding and its covariates in neonates","volume":"31","author":"Smits","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1080\/20469047.2017.1408738","article-title":"Reviewing the WHO guidelines of antibiotic use for sepsis in neonates and children","volume":"38","author":"Fuchs","year":"2018","journal-title":"Paediatr. Int. Child Health"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1473-3099(16)30024-X","article-title":"Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines","volume":"16","author":"McMullan","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/tropej\/fmq012","article-title":"Ten days vs. 14 days antibiotic therapy in culture-proven neonatal sepsis","volume":"56","author":"Gathwala","year":"2010","journal-title":"J. Trop. Pediatr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/jpc.13518","article-title":"Seven versus 10 days antibiotic therapy for culture-proven neonatal sepsis: A randomised controlled trial","volume":"53","author":"Rohatgi","year":"2017","journal-title":"J. Paediatr. Child Health"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/bcp.12053","article-title":"Duration of vancomycin treatment for coagulase-negative Staphylococcus sepsis in very low birth weight infants","volume":"76","author":"Linder","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/tropej\/fml054","article-title":"Randomized controlled trial of 7-day vs. 14-day antibiotics for neonatal sepsis","volume":"52","author":"Chowdhary","year":"2006","journal-title":"J. Trop. Pediatr."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Turta, O., and Rautava, S. (2016). Antibiotics, obesity and the link to microbes\u2014What are we doing to our children?. BMC Med., 14.","DOI":"10.1186\/s12916-016-0605-7"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMp1714987","article-title":"The psychology of clinical decision making\u2014Implications for medication use","volume":"378","author":"Avorn","year":"2018","journal-title":"N. Engl. J. Med."}],"container-title":["Healthcare"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9032\/7\/1\/28\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:32:33Z","timestamp":1760185953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9032\/7\/1\/28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["healthcare7010028"],"URL":"https:\/\/doi.org\/10.3390\/healthcare7010028","relation":{},"ISSN":["2227-9032"],"issn-type":[{"value":"2227-9032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,16]]}}}